Genmab A/S (CPH:GMAB)
Denmark · Delayed Price · Currency is DKK | Market Cap | 125.60B |
| Revenue (ttm) | 24.48B |
| Net Income (ttm) | 10.08B |
| Shares Out | 61.60M |
| EPS (ttm) | 159.78 |
| PE Ratio | 12.76 |
| Forward PE | 18.09 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 98,751 |
| Average Volume | 127,599 |
| Open | 2,035.00 |
| Previous Close | 2,031.00 |
| Day's Range | 2,020.00 - 2,053.00 |
| 52-Week Range | 1,157.00 - 2,153.00 |
| Beta | 0.79 |
| RSI | 61.32 |
| Earnings Date | Nov 6, 2025 |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no... [Read more]
Financial Performance
In 2024, Genmab's revenue was $2.99 billion, an increase of 22.32% compared to the previous year's $2.44 billion. Earnings were $1.09 billion, an increase of 68.72%.
Financial numbers in USD Financial StatementsNews
Artisan International Small-Mid Fund Q3 2025 Performance Review
Security selection in industrials and a notable overweight to the software industry within information technology were the key detractors from relative returns. Health care is among the three weakest ...
Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami
Media Release COPENHAGEN, Denmark; November 24, 2025 Genmab A/S (Nasdaq: GMAB) announced today that its C hief F inancial O fficer Anthony Pagano will participate in a fireside chat at the Citi Globa...
Genmab A/S (GMAB) Presents at Jefferies London Healthcare Conference 2025 Transcript
Genmab A/S (GMAB) Jefferies London Healthcare Conference 2025 November 19, 2025 7:00 AM EST Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - Executive VP & CFO Con...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; November 20, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 6,933 restricted stock units and 7,377 warrants to ...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; November 19, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
FDA Greenlights AbbVie And Genmab's EPKINLY Combo For Relapsed Or Refractory Follicular Lymphoma
(RTTNews) - AbbVie Inc. (ABBV) announced that the FDA has approved EPKINLY in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lym...
Genmab Secures FDA Approval Of EPKINLY Combination Therapy For R/R Follicular Lymphoma
(RTTNews) - Genmab A/S (GMAB) announced that the U.S. Food and Drug Administration approved EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) for the treatment o...
Genmab Announces Pricing Of Private Offering Of Senior Secured Notes And Senior Unsecured Notes
(RTTNews) - Genmab A/S (GMAB) announced that the company and its wholly owned subsidiary Genmab Finance LLC have priced their offering of $1.5 billion of 6.250% senior secured notes due 2032 and $1.0 ...
Genmab Announces Pricing of Private Offering of Senior Secured Notes and Senior Unsecured Notes and Completion of Syndication of New Senior Secured Term Loan Facility
Media Release COPENHAGEN, Denmark; November 18, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) have priced thei...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; November 18, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 32,059 shares as a consequence of the exercise of employee warrants. The incr...
Major Victory For Genmab As Epkinly Receives FDA Approval For Type Of Pretreated Blood Cancer
The U.S. Food and Drug Administration approved Genmab A/S (NASDAQ: GMAB) Epkinly (epcoritamab-bysp) on Tuesday with lenalidomide and rituximab for relapsed or refractory follicular lymphoma (FL) . Th...
AbbVie, Genmab win FDA label expansion for Epkinly in follicular lymphoma
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
COPENHAGEN, Denmark; November 18, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) was approved by the U....
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) was approved by the U.S. ...
FDA Approves Genmab's (GMAB) Epkinly for Follicular Lymphoma Treatment
FDA Approves Genmab's (GMAB) Epkinly for Follicular Lymphoma Treatment
Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes
Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (“Genmab”) announced on November 10, 2025, that it and its wholly owned subsidiary Genmab Finance LLC intend to offer, subject to market...
Zscaler To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Piper San...
Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility
Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) intend to offer,...
Genmab A/S (GMAB) Q3 2025 Earnings Call Transcript
Genmab AS (GMAB) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ...
Genmab AS (GMAB) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic Investments Propel Financial Success
Q3 2025 Genmab A/S Earnings Call Transcript
Q3 2025 Genmab A/S Earnings Call Transcript
Genmab Nine-Mont Profit Rises
(RTTNews) - Genmab A/S (GMAB) Thursday reported net profit of 932 million euros or 14.90 euros per share, compared to 581 million euros or 8.99 euros per share last year.
Genmab (GMAB) Expects Revenue Boost by 2025 Due to Increased Sales and Collaborations
Genmab (GMAB) Expects Revenue Boost by 2025 Due to Increased Sales and Collaborations
Genmab to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference in London
Media Release COPENHAGEN, Denmark; November 5, 2025 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan Van de Winkel and C hief F inancial O fficer Anthony Pagano will par...